- Home
- AMLX vs XERS Comparison
AMLX vs XERS Comparison
Compare AMLX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- XERS
- Stock Information
- Founded
- AMLX 2014
- XERS 2005
- Country
- AMLX United States
- XERS United States
- Employees
- AMLX N/A
- XERS N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- XERS Health Care
- Exchange
- AMLX Nasdaq
- XERS Nasdaq
- Market Cap
- AMLX 749.9M
- XERS 752.7M
- IPO Year
- AMLX 2022
- XERS 2018
- Fundamental
- Price
- AMLX $8.00
- XERS $7.68
- Analyst Decision
- AMLX Strong Buy
- XERS Strong Buy
- Analyst Count
- AMLX 7
- XERS 7
- Target Price
- AMLX $12.00
- XERS $6.79
- AVG Volume (30 Days)
- AMLX 1.0M
- XERS 3.2M
- Earning Date
- AMLX 08-07-2025
- XERS 08-07-2025
- Dividend Yield
- AMLX N/A
- XERS N/A
- EPS Growth
- AMLX N/A
- XERS N/A
- EPS
- AMLX N/A
- XERS N/A
- Revenue
- AMLX N/A
- XERS $246,025,000.00
- Revenue This Year
- AMLX N/A
- XERS $35.31
- Revenue Next Year
- AMLX N/A
- XERS $19.65
- P/E Ratio
- AMLX N/A
- XERS N/A
- Revenue Growth
- AMLX N/A
- XERS 35.62
- 52 Week Low
- AMLX $2.05
- XERS $2.48
- 52 Week High
- AMLX $8.72
- XERS $7.72
- Technical
- Relative Strength Index (RSI)
- AMLX 53.91
- XERS 87.02
- Support Level
- AMLX $7.48
- XERS $7.13
- Resistance Level
- AMLX $8.49
- XERS $7.61
- Average True Range (ATR)
- AMLX 0.40
- XERS 0.41
- MACD
- AMLX -0.06
- XERS 0.21
- Stochastic Oscillator
- AMLX 51.49
- XERS 98.60
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).